タイトル | Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. |
---|
ジャーナル・号・ページ | Mol. Cancer Ther., Vol. 15, Page 2273-2281, Year 2016 |
---|
掲載日 | 2016年8月1日 (構造データの登録日) |
---|
著者 | Chen, P. / Lee, N.V. / Hu, W. / Xu, M. / Ferre, R.A. / Lam, H. / Bergqvist, S. / Solowiej, J. / Diehl, W. / He, Y.A. ...Chen, P. / Lee, N.V. / Hu, W. / Xu, M. / Ferre, R.A. / Lam, H. / Bergqvist, S. / Solowiej, J. / Diehl, W. / He, Y.A. / Yu, X. / Nagata, A. / VanArsdale, T. / Murray, B.W. |
---|
リンク | Mol. Cancer Ther. / PubMed:27496135 |
---|
手法 | X線回折 |
---|
解像度 | 2.27 - 2.8 Å |
---|
構造データ | PDB-5l2i: The X-ray co-crystal structure of human CDK6 and Palbociclib. 手法: X-RAY DIFFRACTION / 解像度: 2.75 Å PDB-5l2s: The X-ray co-crystal structure of human CDK6 and Abemaciclib. 手法: X-RAY DIFFRACTION / 解像度: 2.27 Å PDB-5l2t: The X-ray co-crystal structure of human CDK6 and Ribociclib. 手法: X-RAY DIFFRACTION / 解像度: 2.37 Å PDB-5l2w: The X-ray co-crystal structure of human CDK2/CyclinE and Dinaciclib. 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å |
---|
化合物 | ChemComp-LQQ: 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE / パルボシクリブ / 薬剤, 阻害剤*YM
ChemComp-6ZV: N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]py / LY-2835219 / 薬剤, 阻害剤*YM
ChemComp-6ZZ: 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide / リボシクリブ / 薬剤, 阻害剤*YM
ChemComp-1QK: 3-[({3-ethyl-5-[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl}amino)methyl]-1-hydroxypyridinium
|
---|
由来 | homo sapiens (ヒト)
|
---|
キーワード | Transferase/Transferase Inhibitor / cyclin-dependent kinase / kinase inhibitor / kinase selectivity / Transferase-Transferase Inhibitor complex / Transferase/Cell Cycle/Inhibitor / Transferase-Cell Cycle-Inhibitor complex |
---|